Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, side effects and when it could reach patients.

Patients — and their doctors — have been desperate for a more effective pancreatic cancer treatment for decades. Now one ...

Pancreatic cancer incidence is rising among younger adults, particularly those aged 15 to 39, due to lifestyle and genetic factors. Key risk factors include obesity, smoking, alcohol consumption, and ...

Pancreatic cancer treatment relies on surgery, chemotherapy, and radiation, with surgery for non-metastatic, technically resectable tumors. Advances in chemotherapy, neoadjuvant approaches, and ...

High doses of vitamin C could be a new breakthrough in treating cancer. The University of Iowa Health Care Carver College of Medicine has shared results from a randomized, phase 2 trial testing the ...

The data published in NEJM reflect outcomes in the PDAC cohort from the RMC-6236-001 trial (NCT05379985), an open-label, multicenter Phase 1/2 trial evaluating daraxonrasib monotherapy in patients ...

Pancreatic adenocarcinoma remains one of the most aggressive and difficult-to-treat solid tumor malignancies, with a high mortality-to-incidence ratio. Globally, pancreatic cancer ranks 12th in terms ...

Carolyn Gusoff has covered some of the most high profile news stories in the New York City area and is best known as a trusted, tenacious, consistent and caring voice of Long Island's concerns. For ...

A new UCLA investigator-initiated study sponsored by the UCLA Health Jonsson Comprehensive Cancer Center has found that adding immunotherapy to standard chemotherapy before surgery is safe and shows ...

Most people don’t find out they have pancreatic cancer until the cancer has already gone somewhere it shouldn’t be. There are ...

Most patients with pancreatic cancer report they were never offered the opportunity to participate in clinical trials.A ...